S-甲基异硫脲对大鼠门脉高压症食管静脉曲张的影响

目的观察诱导型一氧化氮合酶抑制剂SMT对大鼠门脉高压症食管静脉曲张的影响。方法健康雄性SD大鼠60只随机分为5组,假手术组、模型组、低剂量组、中剂量组和高剂量组。假手术组仅分离门静脉、左肾上腺静脉关腹,其余组门脉缩窄两步法加左肾上腺静脉结扎,建立门脉高压症食管静脉曲张模型。假手术组与模型组手术后给予腹腔注射生理盐水,其余3组手术后给予腹腔注射不同浓度SMT。手术后21 d,检测大鼠门脉血中TNOS、iNOS的活性及NO的浓度,免疫组化CD34标记食管血管内皮,测量每组大鼠食管横切面黏膜下血管的数目、面积。结果模型组大鼠门脉血中TNOS活性与iNOS活性以及NO浓度和食管黏膜下血管数目,血管平均截面积,血管总面积均较假手术组显著升高（P〈0.01）。中、高剂量组大鼠门脉血中TNOS活性与iNOS活性以及NO浓度和食管黏膜下血管的数目、血管平均面积、血管总面积较模型组均显著下调（P≤0.01）。结论大鼠门脉高压食管静脉曲张的发病机制中有NO参与,门脉缩窄型门脉高压食管静脉曲张病中NO主要由iNOS生成,SMT对大鼠门脉高压食管静脉曲张可能具有一定保护作用。     

重组人生长激素对梗阻性黄疸大鼠sIgA、EGF的影响

目的：观察重组人生长激素对梗阻性黄疸大鼠sIgA、EGF的影响。方法：Wistar大鼠60只随机分4组（n=15）：假手术对照组（A组）、胆总管结扎组（B组）、胆总管结扎＋rhGH治疗1周组（C组）、胆总管结扎＋rhGH治疗2周组（D组）。除A组外,其余各组将胆总管结扎,致胆总管完全梗阻。A组和B组术后2周处死大鼠;C组于术后开始,在双后肢内侧轮流皮下注射rhGH 0.75U.kg^-1.d^-1,1周后处死;D组于术后开始,在双后肢内侧轮流皮下注射rhGH 0.75U.kg^-1.d^-1,2周后处死。各组均无菌操作,在麻醉成功后开腹直视下获取标本,测定TB、ALP、PA、IGF-I、sIgA、EGF等。结果：大鼠梗阻性黄疸时,B、C、D组血中PA、IGF-I及胃肠液中sIgA、EGF降低,血中TB、ALP升高,与A组比较均具有显著性差异（P〈0．05）;而给予外源性生长激素的c组、D组胃肠液中sIgA、EGF降低幅度明显低于B组（P〈0．05）,且梗阻性黄疸大鼠细菌移位率也明显低于B组。结论：外源性生长激素,能保护梗阻性黄疸大鼠的肝脏功能,以及肠道的机械屏障功能和免疫屏障功能,减少肠道细菌移位的发生。     

双侧迷走神经和颈总动脉联合切断法建立急性脑缺血大鼠模型

目的建立一种操作简单的急性脑缺血动物模型。方法取雄性Wistar大鼠40只,体重200～230g,手术前禁食12 h,自由饮水,随机分为对照组A、B、C组及模型D组,共4组,每组10只。即A组:假手术组,仅切开颈部两侧皮肤,分离双侧颈总动脉和迷走神经,不切断,然后缝合;B组:仅切断双侧颈部迷走神经;C组:结扎并切断双侧颈总动脉(CCA);D组:联合组,即结扎并切断双侧颈总动脉,同时切断双侧颈部迷走神经。观察各组大鼠手术后的脑缺血症状,记录各组大鼠在8h内的死亡情况,超过8h死亡的动物按8h计,计算死亡率和死亡时间。结果 A组大鼠没有脑缺血症状,无死亡;B组大鼠无脑缺血症状,呼吸变慢变深,心率血压上升,但无死亡;C组大鼠部分出现脑缺血症状,眼睑下垂,活动能力低下,自发运动减少,有些大鼠术后自发运动增加,在8 h内无死亡;D组大鼠大多数出现较为明显的脑缺血症状,在8 h内全部死亡。结论采取同时结扎并切断大鼠双侧颈总动脉和双侧颈部迷走神经的方法,可以建立急性脑缺血大鼠动物模型,此方法具有手术简单,成功率高,术后动物缓慢死亡的特点。     

多重干预RAAS对大鼠慢性心功能不全心室重构及血钾的影响

目的探讨多重干预RAAS对大鼠慢性心功能不全心室重构及血钾的影响。方法实验采用缩窄大鼠腹主动脉法建立慢性压力负荷致心功能不全动物模型,选6周龄20只雌性SD大鼠,随机分4组(每组5只),B组(手术模型组)、C组(卡托普利组)、D组(卡托普利+缬沙坦组)、E组(卡托普利+缬沙坦+螺内酯组),另随机抽取5只同龄雌性SD大鼠假手术作为对照(A组)。给药8周后用Doppler超声心动图检测大鼠心脏结构和心功能各项参数的变化,放射免疫法测定血浆AngⅡ,ALDO浓度,并生化检测血钾水平。结果腹主动脉结扎后第9周,与A组比较,B组舒张末期室间隔厚度(IVSTD)、舒张末期左室后壁厚度(LVPWTD)、相对室壁厚度(RWT)、左室重量(LVM)、左室重量与体重比(LVM/BW)均显著提高(P<0.05);C、D、E组与B组相比,LVM,LVM/BW下降显著(P<0.05)。各药物干预组(C、D、E)血浆AngⅡ,ALDO水平明显低于B组(P<0.05),以联合应用螺内酯组明显。各药物干预组与A组和B组相比较,血钾水平差异无显著性(P>0.05)。结论联合应用卡托普利、缬沙坦及螺内酯多重干预RAAS能明显改善大鼠慢性心功能不全心室重构,对血钾无明显影响。     

SR 59230A对心衰大鼠心脏MicroRNAs表达的影响

目的：观察β3肾上腺素受体（β3-AR）对心衰大鼠心脏MicroRNAs表达的影响及可能的作用机制。方法：大鼠冠脉左前降支结扎造成心衰模型,假手术大鼠只穿线不结扎。造模成功大鼠再随机分为：心衰组（CHF control group）和心衰+SR 59230A组（CHF+SR group）;假手术大鼠也随机分为假手术组（Sham group）和假手术+SR 59230A组（Sham+SR group）。Sham+SR组和CHF+SR组每天两次腹腔注射SR （85 mmol/L,1 ml）,连续注射7周。结果：①miScript miRNA PCR Arrays显示,在体阻断β3-AR后,假手术组与心衰组有18种MicroRNAs共同表达下调;经文献比对,与NF-κB相关的MicroRNAs有6种,分别为miR-125b-5p,miR-143-3p,miR-145-5p,miR-26a-5p,miR-30a-5p和miR-320-5p。②大鼠心脏组织切片观察到NF-κB在心衰大鼠心肌细胞核与细胞质中均有分布,而p53在心肌细胞质分布较多,NF-κB和p53表达明显高于假手术组（P<0.05）。阻断β3-AR后,心衰组心脏NF-κB和p53表达显著减少（P<0.05）,而假手术组NF-κB和p53表达略增加（P<0.05）。③Western blot结果发现心衰大鼠NF-κB p65表达高于假手术组（P<0.05）,给予β3-AR阻断剂后,心衰组心脏NF-κB p65和p53-Phospho-Serine 15表达均下降（P<0.05）,而假手术组心脏阻断β3-AR后,NF-κB、p53和p53-Phospho-Serine 15表达均增加（P<0.05）。结论：阻断β3肾上腺素受体有利于缓解心衰大鼠心脏的损伤;β3-AR可引起MicroRNAs表达变化且与NF-κB信号通路有关。     

门静脉高压症大鼠肠系膜组织内皮素B受体表达的变化

目的:探讨胆汁性肝纤维化引起的门静脉高压症(PHT)大鼠肠系膜组织内皮素B受体表达(ETBR)的变化.方法:取体重250±10 g左右的清洁级SD雄性大鼠30只,根据体重随机分为假手术组、模型组,模型制作采用胆总管结扎的方法造成大鼠胆汁性肝纤维化.术后2周和4周分别测定各组的门静脉压力,应用免疫组化和免疫印迹的方法观察肠系膜组织ETBR的表达.结果:术后2周和4周模型组门静脉压力显著升高,分别为11.89±1.38 mmHg和16.34±1.63 mmHg.免疫组化显示假手术组肠系膜组织ETBR主要见于细动脉内皮细胞,而模型组大鼠ETBR的表达不仅见于细动脉内皮细胞,细动脉平滑肌细胞和微动脉表达也很显著.免疫印迹发现假手术组肠系膜组织ETBR含量很少,模型组大鼠ETBR表达明显增多.结论:正常大鼠肠系膜血管组织ETBR表达较少,随着肝组织损伤加剧和PHT形成,肠系膜组织ETBR表达明显增加,可能参与胆汁性肝硬化PHT形成过程.     

瑞舒伐他汀对压力超负荷型心肌肥厚大鼠TGF-β1表达的影响

目的:观察瑞舒伐他汀对大鼠压力超负荷型心肌肥厚的作用,并探讨其对TGF-β1表达的影响.方法:将SD大鼠随机分为5组.除假手术组外各组通过不完全结扎大鼠腹主动脉构建心肌肥厚模型,A为假手术组,B为单纯手术组,C为卡托普利组(50mg/kgod),D组为瑞舒伐他汀小剂量组(2 mg/kgod),E为瑞舒伐他汀大剂量组(4 mg/kgod),各组动物术前一周始灌胃给予相应药物直至术后4周,A、B纽给予等量生理盐水.给药第5周末,测定各组大鼠血压和心脏质量指教;采用RT-PCR法和免疫组化法检测左室心肌组织中TGF-β1mRNA和TGF-β1蛋白表达.结果:术后4周各组动物血压和HMI较A组明显增加(P<0.01或P<0.05),而C、D、E组较B组有显著下降(P<0.01或P<0.05);同时各治疗组左室心肌组织中TGF-β1 mRNA和TGF-β1蛋白表达较B组有显著下降(P<0.01),且C组抑制表达较D、E组更为显著(P<0.05或P<0.01).结论:瑞舒伐他汀可有效的缓解压力超负荷诱导的大鼠心肌肥厚,且作用类似卡托普利,其可能通过降低左室心肌TGF-β1表达,影响TGF-β信号转导产生作用.     

复方高支链氨基酸对肝硬化大鼠肝功能及营养状况的影响

将SD雄性大鼠用四氯化碳处理建立肝硬化大鼠模型,并随机分为A、B、C三组,A组大鼠给予静脉输注生理盐水,B组、C组大鼠分别给予输注等量的普通氨基酸注射液和复方高支链氨基酸注射液,分别于实验第0d、第14d测定大鼠体质量、肝功能指标及营养学指标水平。实验结束后,B、C两组大鼠体质量明显增加,与A组相比,B、C两组大鼠肝功能各指标水平显著降低,血清蛋白水平显著升高,且C组相比,B组大鼠肝功能水平与血清蛋白水平改善作用更为明显(p<0.05)。说明复方高支链氨基酸能改善肝硬化大鼠的肝功能指标,抑制血浆蛋白分解,有效控制肝硬化病症的进一步恶化。     

血必净注射液对梗阻性黄疸大鼠血清内毒素及肿瘤坏死因子-alpha水平的影响

目的：探究血必净注射液对梗阻性黄疸大鼠血清内毒素(ETX)及肿瘤坏死因子-alpha(TNF-alpha)水平的影响。方法：选取雄性SD 大 鼠60 只,随机分为假手术(A)组、梗阻性黄疸(B)组、血必净干预(C)组,每组20 只。A组不结扎胆总管,B、C两组结扎胆总管。术后 七天,C 组每日皮下注射血必净4 mL/Kg,A 组、B 组用等量生理盐水替代,持续用药一周。实验两周后,检测和比较各组大鼠血清 ETX、TNF-alpha、总胆红素(TBIL)及直接胆红素(DBIL)水平。结果：术后两周,A组血清TBIL、DBIL 水平显著低于B、C两组;B组血 清TBIL、DBIL 水平显著高于C 组,差异均有统计学意义(P<0.05)。B组血清ETX和TNF-alpha水平显著高于A、C 组,差异均有统计 学意义(P<0.05)。结论：血必净注射液可能通过降低血清ETX和TNF-alpha含量改善梗阻性黄疸。     

多因素诱导大鼠肝硬化模型及其对CYPlA2、CYP2C9／10和CYP2C19表达的影响

目的：研究不同因素诱导肝硬化大鼠体内细胞色素酶（CYP）1A2、CYIr2C9／10和CYP2C19的表达变化。方法：4组大鼠即正常对照组（NC组）、四氯化碳组（Ca4组）、致癌物组（TAA组）及免疫组（BSA组）（n=10）,分别以非那西丁15ms／ks、甲苯磺丁脲0．6me／kg和奥美拉唑15mg／kg进行联合灌胃给药并测定血药浓度。结果：与NC组相比,cck组和’11从组的非那西丁与奥美拉唑的曲线下面积AUC均显著升高（P〈O．01）,清除率cL均显著下降（P〈O．05）,峰浓度C-均显著升高（P〈O．01）,半衰期1／2均显著下降（P〈0．05）;甲苯磺丁脲各参数无统计学差异（P〉O．05）。结论：肝硬化大鼠体内CYPlA2和CYP2C19酶表达明显降低,CYP2Cg／10酶表达变化不明显。     

A novel canine model of portal vein stenosis plus thioacetamide administration-induced cirrhotic portal hypertension with hypersplenism

Current large animal models that could closely resemble the typical features of cirrhotic portal hypertension in human have not been well established. Thus, we aimed to develop and describe a reliable and reproducible canine cirrhosis model of portal hypertension. A total of 30 mongrel dogs were randomly divided into four groups: 1 (control; n = 5), 2 (portal vein stenosis [PVS]; n = 5], 3 (thioacetamide [TAA]; n = 5), and 4 (PVS plus TAA; n = 15). After 4-months modeling period, liver and spleen CT perfusion, abdominal CT scans, portal hemodynamics, gastroscopy, hepatic function, blood routine, the bone marrow, liver, and spleen histology were studied. The animals in group 2 (PVS) developed extrahepatic portosystemic collateral circulation, particularly esophageal varices, without hepatic cirrhosis and portal hypertension. Animals from group 3 (TAA) presented mild cirrhosis and portal hypertension without significant symptoms of esophageal varices and hypersplenism. In contrast, animals from group 4 (PVS + TAA) showed well-developed micronodular and macronodular cirrhosis, associated with significant portal hypertension and hypersplenism. The combination of PVS and TAA represents a novel, reliable, and reproducible canine cirrhosis model of portal hypertension, which is associated with the typical characteristics of portal hypertension, including hypersplenism.     

Increased plasma volume in two models of portal hypertension in the rat: cirrhosis of the liver and partial portal vein ligation

Portal hypertension has been studied in the rat to see if it is associated to altered blood volume composition, as it has been shown in other species. Plasma volume was measured by isotope dilution using 99mTc labelled albumin in three groups of male Sprague-Dawley rats: normal rats (controls), partially ligated portal vein rats and rats with Cl4C induced cirrhosis. Plasma volume was significantly higher in rats with portal hypertension due to partially ligated portal vein and cirrhosis than in control animals. Similarly, the calculated blood volume was also significantly higher in the portal hypertensive animals than in control group. Portal hypertension in the rat, therefore, has been demonstrated to be associated to a marked hypervolemia and this finding should be taken into consideration in haemodynamic and pharmacokinetic studies in portal hypertensive rat models.     

脾切除及贲门周围血管离断术对肝硬化门静脉高压患者肝脏血流动力学的影响及其术后门静脉血栓形成的因素分析

目的:探讨脾切除及贲门周围血管离断术对肝硬化门静脉高压患者肝脏血流动力学的影响,并分析患者术后门静脉血栓形成的危险因素。方法:选择2016年1月-2017年12月在我院进行脾切除及贲门周围血管离断术的96例肝硬化门静脉高压患者,于术前、术后1d、3d、7d采用彩色多普勒超声对患者的肝脏血流动力学指标进行动态监测。统计术后7d内患者门静脉血栓的发生率,并将患者分为血栓组(n=28)和无血栓组(n=68),对两组患者的一般资料、手术指标、彩色多普勒超声监测指标等进行单因素分析,并采用Logistic多因素回归分析门静脉血栓形成的危险因素。结果:患者在术前、术后1d、3d、7d时的门静脉内径、最大流速、血流量呈逐渐降低的趋势,肝动脉内径、最大流速、血流量呈逐渐升高的趋势,且各时间点间两两比较差异有统计学意义(P0.05)。术后7d内有28例患者出现门静脉血栓,发生率为29.17%。血栓组和无血栓组患者在性别、年龄、体质量指数、手术时间、术前门静脉流速比较差异无统计学意义(P0.05);血栓组患者Child-Pugh分级为B级比例、术中出血量、脾质量、腹水量、术前门静脉内径均高于无血栓组,术后门静脉内径、术后门静脉流速均低于无血栓组(P0.05)。经Logistic多因素回归分析显示,患者术后门静脉内径、术后门静脉流速是门静脉血栓形成的危险因素(P0.05)。结论:行脾切除及贲门周围血管离断术的肝硬化门静脉高压患者术后进行肝脏血流动力学监测,有助于患者术后的疗效判断,且术后门静脉内径、术后门静脉流速是门静脉血栓形成的危险因素。     

16层螺旋CT灌注成像对肝硬化血流状态的评估及与肝硬化程度的相关性研究

目的:探讨16层螺旋CT灌注成像对肝硬化血流状态的评估价值及其与肝硬化程度的相关性。方法:选取2014年1月至2016年1月于我院接受诊治的肝硬化患者126例作为肝硬化组,根据Child-Pugh分级分为A组(Child A级,n=35例)、B组(Child B级,n=50例)、C组(Child C级,n=41例)。另选取同期于我院接受体检的健康人员100例作为对照组。应用16层螺旋CT对受试者肝脏、脾脏、主动脉以及门静脉的层面进行CT动态增强扫描,对比CT灌注参数,采用Pearson相关性分析分析CT灌注参数与肝硬化病情严重程度的关系。结果:肝硬化组肝动脉灌注量(HAP)、肝动脉灌注指数(HPI)、肝脏血流量(TBV)以及平均通过时间(MTT)均明显高于对照组,而门静脉灌注量(PVP)、总肝灌注量(TLP)均明显低于对照组(P0.05)。A组患者HAP、HPI均明显高于C组,而PVP与TLP均明显低于C组,差异有统计学意义(P0.05);两组TBV、MTT比较无统计学差异(P0.05);而A组与B组相比以及B组与C组相比,各项CT灌注参数均无统计学差异(P0.05)。肝硬化患者病情严重程度与HAP、HPI均呈正相关关系(P0.05),而与PVP、TLP均呈负相关关系(P0.05)。结论:16层螺旋CT灌注成像对肝硬化血流状态具有一定的评估价值,且CT灌注参数的水平变化与肝硬化患者病情严重程度存在密切相关。     

Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis

Background

Increased intra-hepatic resistance to portal blood flow is the primary factor leading to portal hypertension in cirrhosis. Up-regulated expression of cyclooxygenase-2 (COX-2) in the cirrhotic liver might be a potential target to ameliorate portal hypertension.

Objective

To verify the effect of celecoxib, a selective inhibitor of COX-2, on portal hypertension and the mechanisms behind it.

Methods

Cirrhotic liver model of rat was established by peritoneal injection of thiacetamide (TAA). 36 rats were randomly assigned to control, TAA and TAA+celecoxib groups. Portal pressures were measured by introduction of catheters into portal vein. Hepatic fibrosis was assessed by the visible hepatic fibrotic areas and mRNAs for collagen III and α-SMA. The neovasculature was determined by hepatic vascular areas, vascular casts and CD31 expression. Expressions of COX-2, vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2) and related signal molecules were quantitated.

Results

Compared with TAA group, the portal pressure in TAA+celecoxib group was significantly decreased by 17.8%, p<0.01. Celecoxib treatment greatly reduced the tortuous hepatic portal venules. The data of fibrotic areas, CD31expression, mRNA levels of α-SMA and collagen III in TAA+celecoxib group were much lower than those in TAA group, p<0.01. Furthermore, the up-regulation of hepatic mRNA and protein levels of VEGF, VEGFR-2 and COX-2 induced by TAA was significantly inhibited after celecoxib treatment. The expressions of prostaglandin E2 (PGE2), phosphorylated extracellular signal-regulated kinase (p-ERK), hypoxia-inducible factor-1α (HIF-1α), and c-fos were also down-regulated after celecoxib treatment.

Conclusions

Long term administration of celecoxib can efficiently ameliorate portal hypertension in TAA rat model by its dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. The anti-angiogenesis effect afforded by celecoxib may attribute to its modulation on VEGF/VEGFR-2 through the down-regulation of integrated signal pathways involving PGE2- HIF-1α- VEGF and p-ERK- c-fos- VEGFR-2.     

ET-1 and TNF-alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats

Common bile duct ligation (CBDL) triggers a molecular cascade resulting in the hepatopulmonary syndrome (HPS). Both increased hepatic endothelin-1 (ET-1) production and pulmonary vascular ET(B) receptor expression with stimulation of endothelial nitric oxide synthase and TNF-alpha mediated inducible nitric oxide synthase and heme oxygenase-1 expression in pulmonary intravascular macrophages occur. Whether biliary cirrhosis is unique in triggering ET-1 and TNF-alpha alterations and HPS is unknown. We evaluated for HPS in rat prehepatic portal hypertension [partial portal vein ligation (PVL)], biliary (CBDL) and nonbiliary [thioacetamide treatment (TAA)] cirrhosis, and assessed ET-1 infusion in normal and PVL animals. Control, PVL, CBDL, TAA-treated, and ET-1-infused PVL animals had ET-1 and TNF-alpha levels measured and underwent molecular and physiological evaluation for HPS. HPS developed only in biliary cirrhosis in association with increased plasma ET-1 and TNF-alpha levels and the development of established molecular changes in the pulmonary microvasculature. In contrast, PVL did not increase ET-1 or TNF-alpha levels and TAA treatment increased TNF-alpha levels alone, and neither resulted in the full development of molecular or physiological changes of HPS despite portal pressure increases similar to those after CBDL. Exogenous ET-1 increased TNF-alpha levels and triggered HPS after PVL. Combination of ET-1 and TNF-alpha overproduction is unique to biliary cirrhosis and associated with experimental HPS. ET-1 infusion increases TNF-alpha levels and triggers HPS in prehepatic portal hypertension. ET-1 and TNF-alpha interact to trigger pulmonary microvascular changes in experimental HPS.     

Portal and arterial free and conjugated noradrenaline in two models of portal hypertension in rats

Free and conjugated noradrenaline concentrations were measured in portal-venous and arterial plasma from sham-operated rats or rats with portal hypertension. Two types of portal hypertension in rats were evaluated: in portal vein stenosed rats, the liver was normal, whereas cirrhosis developed in bile duct ligated rats. In cirrhotic rats, arterial free noradrenaline level was higher than in both sham-operated and portal-stenosed rats, this indicating that enhanced sympathetic nervous activity depends on the development of cirrhosis. In all groups of rats, portal venous plasma free noradrenaline was higher than arterial plasma level, indicating a production of noradrenaline by splanchnic organs. Arterial noradrenaline level may be mainly dependent on this splanchnic production in case of portal hypertension. Sulfoconjugated and glucuronoconjugated noradrenaline plasma levels were similar in the three groups of rats. This shows that alteration in conjugation is not likely to be a major factor in the abnormal circulating levels of free noradrenaline observed in cirrhotic rats.     

Protective effects of Rosmarinus tomentosus ethanol extract on thioacetamide-induced liver cirrhosis in rats

The capability of an ethanol extract of Rosmarinus tomentosus to protect rat liver in an experimental model of cirrhosis induced by thioacetamide (TAA) has been evaluated. Four groups of rats were used: Two of them received 300 mg TAA/l in the drinking water for 3 months while the other two, which served as controls, were given water ad libitum. During the same period and for each one of the treatments, one group received a semi-purified (SP) diet and the other one was fed the same diet supplemented with 1% of the dry residue obtained from R. tomentosus ethanol extract (SP+E). There was a significant reduction of TAA toxicity in rats fed the SP+E diet, as assessed by plasma and liver biochemical markers, and by liver histopathology. Plasma total protein concentration was restored, urea concentration and plasma alkaline phosphatase and gamma-glutamyl-transferase activities were reduced. A significant correction of plasma fatty acids concentrations was also evident. Hepatic alkaline phosphatase and gamma-glutamyl-transferase activities were significantly reduced in animals fed SP+E diet and glucose-6-phosphatase activity was significantly enhanced. The results suggest that R. tomentosus ethanol extract administered in the diet affords protection against TAA-induced cirrhosis, preventing most of the histological changes and functionality alterations own to this experimental pathology.     

不同入肝血流阻断方式对荷瘤小鼠肝功能影响的实验研究

目的:探讨不同血流阻断方式对荷瘤小鼠肝细胞功能的影响。方法:选择昆明小鼠24只随机分为三组,正常对照组(Suspe-nded operation,SO)、肝门阻断组(Occlusion of the portal triad,OPT)、保留肝动脉持续阻断门静脉(Occlusion of portal vein,OPV)各8只。采用门静脉注射肿瘤的方法建立肝癌模型,建模后3天采用阻断范围为左外叶和中叶、阻断时间为60分钟的入肝血流阻断方式,复流后5天后,通过测量3组对肝脏的缺血再灌注损伤程度以及病理学变化来评价不同血流阻断方式对肝细胞功能影响的程度。结果:门静脉注射小鼠肝癌细胞8天后,对照组测量小鼠正常丙氨酸氨基转移酶(ALT)值为66.5±22.3 IU/L,OPT组值为276.3±80.5 IU/L,OPV组值为89.6±28.4 IU/L,两组比较有统计学差异(P0.01);对照组测量小鼠正常天冬氨酸氨基转移酶(AST)值为301.3±126.7 IU/L,OPT组值为1126.4±285.5 IU/L,OPV组值为438.6±150.7 IU/L,两组比较有统计学差异(P0.01),病理组织学OPV组肝细胞损伤程度明显较OPT组轻。结论:保留肝动脉持续阻断门静脉可以减轻荷瘤小鼠肝脏的缺血再灌注损伤。